E
Evelyne Callet-Bauchu
Researcher at Lyon College
Publications - 95
Citations - 4562
Evelyne Callet-Bauchu is an academic researcher from Lyon College. The author has contributed to research in topics: Lymphoma & Splenic marginal zone lymphoma. The author has an hindex of 33, co-authored 95 publications receiving 4220 citations. Previous affiliations of Evelyne Callet-Bauchu include HCL Technologies & University of Lyon.
Papers
More filters
Journal ArticleDOI
Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32).
Quangeng Zhang,Reiner Siebert,Minhong Yan,Bernd Hinzmann,Xiaoli Cui,Liquan Xue,Karen M. Rakestraw,Clayton W. Naeve,Georg Beckmann,Dennis D. Weisenburger,Warren G. Sanger,Hadwiga Nowotny,Michael Vesely,Evelyne Callet-Bauchu,Gilles Salles,Vishva M. Dixit,André Rosenthal,Brigitte Schlegelberger,Stephan W. Morris,Stephan W. Morris +19 more
TL;DR: Mucosa-associated lymphoid tissue (MALT) lymphomas most frequently involve the gastrointestinal tract and are the most common subset of extranodal non-Hodgkin lymphoma (NHL), and overexpression of BCL10, a novel apoptotic signalling gene that encodes an amino-terminal caspase recruitment domain (CARD), in MALT lymphomas might have a twofold lymphomagenic effect.
Journal ArticleDOI
Primary thyroid lymphoma is a heterogeneous disease.
Catherine Thieblemont,A Mayer,Charles Dumontet,Y. Barbier,Evelyne Callet-Bauchu,Pascale Felman,Françoise Berger,X Ducottet,C Martin,Gilles Salles,J Orgiazzi,Bertrand Coiffier +11 more
TL;DR: The histological heterogeneity of TL corresponding to different clinical presentations and different prognoses was confirmed, and any routine clinical or biological parameters that could predict the evolution from Hashimoto's thyroiditis to MALT lymphoma were not found.
Journal ArticleDOI
Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients
Françoise Berger,Pascale Felman,Catherine Thieblemont,Thierry Pradier,L. Baseggio,P. A. Bryon,Gilles Salles,Evelyne Callet-Bauchu,Bertrand Coiffier +8 more
TL;DR: Conservative treatments seem recommended for leukemic and splenic subtypes of marginal zone B-cell lymphoma, with survival good with a median survival of 9 years, allowing these lymphomas to be classified as indolent.
Journal ArticleDOI
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Christiane Pott,Eva Hoster,Marie-Hélène Delfau-Larue,Kheira Beldjord,Sebastian Böttcher,Vahid Asnafi,Anne Plonquet,Reiner Siebert,Evelyne Callet-Bauchu,Niels Smedegaard Andersen,Jacques J.M. van Dongen,Wolfram Klapper,Françoise Berger,Vincent Ribrag,Achiel Van Hoof,Marek Trneny,Jan Walewski,Peter Dreger,Michael Unterhalt,Wolfgang Hiddemann,Michael Kneba,Hanneke C. Kluin-Nelemans,Olivier Hermine,Elizabeth Macintyre,Martin Dreyling +24 more
TL;DR: The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma treated within 2 randomized trials of the European MCL Network and emerged to be an independent prognostic factor for RD.
Journal ArticleDOI
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
Estella Matutes,D Oscier,Carlos Montalbán,Françoise Berger,Evelyne Callet-Bauchu,Ahmet Dogan,Pascale Felman,Vito Franco,Emilio Iannitto,Manuela Mollejo,Theodora Papadaki,Ellen D. Remstein,Antonio Salar,Francesc Solé,Kostas Stamatopoulos,Catherine Thieblemont,Alexandra Traverse-Glehen,Andrew Wotherspoon,B. Coiffier,M A Piris +19 more
TL;DR: These guidelines are intended to contribute to the standardization of the diagnosis and treatment of patients with splenic marginal zone lymphoma, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.